The UK has a long track record of cost-effective and compliant medicines manufacturing from leading global companies and has specialised national networks in high value manufacturing (HVM).
Pharmaceutical regulation in the UK is the responsibility of the Medicines and Healthcare products Regulatory Agency (MHRA). It is recognised globally as an authority in its field and its Innovation Office helps businesses clarify product regulatory requirements and find faster routes to market.
More information on pharmaceutical manufacturing in the UK can be found here.
The South-East has one of the largest concentrations of biopharmaceutical companies in the UK, with many of the leading organisations having a base in the Thames Valley.
Boehringer Ingelheim is one of the world’s largest pharmaceutical company, and the largest private one. The company focuses specifically on respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim also recently invested £6m+ in refurbishing and expanding its premises.
Prof Klaus Dugi, UK & Ireland MD at Boehringer Ingelheim
Belgian pharmaceutical giant UCB will be investing £1 billion in R&D over the next five years, including £150-200 million in a new state-of-the-art facility near their existing R&D base in Slough, which will house an early manufacturing site and a hub for UK commercial operations and support around 650 high-skilled jobs.
The decision was announced as part of the Government’s recently published Life Sciences Sector Deal 2.
Alnylam, one of the most promising US biotechnology companies, recently opened its European Drug Development and Commercial Headquarters in Maidenhead. The leading corporate exponent of RNAi therapeutics (RNA interference), which makes it possible to “silence” disease-causing genes; its pioneering drug, patisiran (branded as Onpattro) was recently authorised for use in the EU.
German-owned Bayer, one of the world’s top ten pharmaceutical companies, which operates in the small molecule segment, has its UK Headquarters in Reading, having recently relocated within the region.
At the beginning of October, Bayer opened their flagship LifeHub UK, in Reading, to add to the company’s growing network of innovation hubs.
Oxford BioMedica, a leading gene and cell therapy group, which announced its scheduled expansion for 2019 into new offices in Oxford. The new facility will more than double the bioprocessing capacity of the Group and create up to 100 new, highly skilled positions over the next two years, safeguarding the company’s market-leading position.